Tagged with janssen

Brazil Bruno Costa Gabriel, managing director of Janssen Brazil, provides insights into the transformative market approach successfully implemented by this leading company in Brazil and his main priorities to further leverage the great potential of Janssen’s innovation and impact an ever-increasing number of Brazilian patients.   You display a truly international…

Colombia With Latin America’s best healthcare system in terms of both coverage and quality, Colombia is fast becoming a destination of choice for multinationals, not only to set up shop in the sense of establishing a direct local affiliate, but also for opening regional headquarters and implanting managerial functions. “We are…

Colombia Yolanda Alagón, general manager of Janssen Colombia, discusses the company’s footprint in Colombia and Latin America and her strategy for the affiliate moving forward. You have been appointed General Manager three years ago, becoming one of the first women to lead a pharma company in Latin America. You mentioned your…

Greece Efthymios (Makis) Papataxiarchis, Managing Director of Janssen Pharmaceutical companies, Johnson & Johnson Greece, Malta & Cyprus, on spearheading a large multinational company through the largest economic crisis in Europe. He speaks about Janssen’s portfolio in Greece, how to mitigate challenges in market access, as well as igniting a solutions-driven dialogue…

Singapore The Asia-Pacific region is a vast geographic area, home to almost half of the world’s population and numerous emerging and developed markets with great investment potential for healthcare and life sciences companies. However, the degree of diversity within Asia-Pacific creates formidable challenges for MNCs operating in the region. “APAC is…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…

Mexico Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has been critical to Janssen’s success in a country noteworthy for the complexity of its public health system. You took over…

Pharma Janssen’s company group chairman for Asia Pacific, Kris Sterkens distills the core elements of what it means to be a transformational medical innovator, while exclaiming how this characterization has molded the company’s patient-centric commitments across the region.  When several others have experienced drawback, what factors have best positioned Janssen for…

Pharma Dr. Leisha Daly, Janssen Ireland country director and president of the Irish Pharmaceutical Healthcare Association (IPHA) discusses her presidency and the conclusion of a four-year agreement between IPHA and the Irish government on the supply of medicine. She then highlights Janssen’s leadership in Ireland in terms of ‘open-innovation’ and ‘beyond-the-pill’…

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Pharma The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent double-digit growth over the last four years, while highlighting the advantages of using Hungary as a strategic hub. He also shares his vision for Janssen Academy—an institute set to become…

Pharma Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment with those of its regional neighbors and finds that there is little ground for fair comparison. You have been with…